

Paper # 7
 OCT 03 2000
 RECEIVED
 PATENT & TRADEMARK OFFICE
 OCT 05 2000
 TECH CENTER WASH DC

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: October 3, 2000	ATTY DOCKET NO. 018733/0884 APPLICANT Hans J. HANSEN <i>et al.</i> FILING DATE June 22, 1999	SERIAL NO. 09/337,756 GROUP 1643
---	---	---

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT
2000	A1	4/6/88	EUROPE	—	—	
2000	A2	10/28/92	EUROPE	—	—	
2000	A3	3/5/98				

RECEIVED
 OCT 4 2000
 GROUP 1700

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

2000	A4	B.T. McGuinness <i>et al.</i>	“Phage diabody repertoires for selection of large numbers of bispecific antibody fragments,” <i>Nature Biotechnology</i> , 14:1149-1154 (1996).
2000	A5	M. Alt <i>et al.</i>	“Novel tetravalent and bispecific IgG-like antibody molecules combining single chain diabodies with the immunoglobulin gamma-1 or CH3 region,” <i>FEBS LETT</i> , 454: 90-94 (1999).
2000	A6	T.B. Olafsen <i>et al.</i>	“IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic Cells,” <i>Immunotechnology</i> , 4(2):141-153 (1998).
2000	A7	S.M. Kipriyanov <i>et al.</i>	“Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” <i>J. Mol. Biol.</i> , 293(1):41-56 (1999).

EXAMINER Daniel A. Saunders DATE CONSIDERED 2/7/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

attach Paper 4

Sheet of 1 of 2

FORM PTO 1449 (modified)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

ATTY DOCKET NO.
018733/0884


SERIAL NO.
US 09/337,756

APPLICANT
Hans J. HANSEN et al.

FILING DATE
June 22, 1999

GROUP
1643

Date Submitted to PTO: November 4, 1999



EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

Gus	A1a	G. Hawkins, et al.	"Delivery of Radionuclides to Pretargeted Monoclonal, Antibodies Using Dihydrofolate Reductase and Methotrexate in an Affinity System," <i>Cancer Research</i> , Vol. 53, pp 2368-2373, May 1993.
	A2a	David A. Goodwin, et al.	"Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Labeled Bifunctional Haptens," <i>J. Nucl. Med.</i> , Vol. 29, pp 226-234, 1998.
	A3	Dwight R. Stickney, et al.	"Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma," <i>Cancer Research</i> , Vol. 51, pp 6650-6655, December 15, 1991.
Gus	A4	Emmanuel Gautherot, et al.	"Therapy for Colon Carcinoma Xenografts with Bispecific Antibody-Targeted, Iodine-131-Labeled Bivalent Hapten," <i>Cancer Supplement</i> , Vol. 80, pp 2618-2623, 1997.
	A5	J. Barbet, et al.	"Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium," <i>The Journal of Nuclear Medicine</i> , Vol. 39, No. 7, July 1998.
	A6	Marion H.G.C. Kranenborg, et al.	"Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma," <i>Cancer Research Supplement</i> , Vol. 55, pp 5864s-5867s, December 1, 1995.
Gus	A7	S.R. Cherry, et al.	MICROPET 1: Performance Evaluation of a Very High Resolution Pet Scanner <i>Proceedings of the 44th Annual Meeting Scientific Papers</i> , Vol. 38, No. 5, May 1997 Supplement.

Sheet of **2 of 2**

FORM PTO 1449 (modified)
 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE
 LIST OF REFERENCES CITED BY APPLICANT(S)
 (Use several sheets if necessary)

ATTY DOCKET NO.
 018733/0884

SERIAL NO.
 US 09/337,756

APPLICANT
 Hans J. HANSEN et al.

FILING DATE
 June 22, 1999

GROUP
 1643

Date Submitted to PTO: November 4, 1999

Date Submitted to PTO: November 4, 1995			
JUL	A8	Jochen Schuhmacher, et al.	"Multistep Tumor Targeting in Nude Mice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigraphy with Positron Emission Tomography," <i>Cancer Research</i> , Vol. 55, pp 115-123, January 1, 1995.
JUL	A9	Robert M. Sharkey, et al.	"Development of a Streptavidin--Anti- Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method For Radioimmunotherapy of Colorectal Cancer. Studies in A Colon Cancer Xenograft Model," <i>Bioconjugate Chemical</i> , Vol. 8, No. 4, 1997.
EXAMINER <i>Daniel A. Saunders</i>			DATE CONSIDERED <i>2/7/01</i>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 1 of 2

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: May 18, 2000

ATTY DOCKET NO.
018733/0884SERIAL NO.
09/337,756APPLICANT
Hans J. HANSEN *et al.*FILING DATE
June 22, 1999GROUP
1643

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>zws</i>	A1	5,591,828	07/01/97		530 387.3	

RECEIVED

JUN 22 2000

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT
A2	WO 9604313	02/15/96	INTERNATIONAL	—	—
A3	EP 0623675	11/09/94	EUROPE	—	—
A4	EP 0419387	03/27/91	EUROPE	—	—

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>zws</i>	A5	H. Karacay <i>et al.</i>	"Studies on a humanized anti-CEA x murine anti-(In- DTPA) bispecific antibody construct for radioimmunotherapy of CEA-positive tumors," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , Vol. 40, p 644 (March 1999).
<i>zws</i>	A6	H. Karacay <i>et al.</i>	"Pretargeting studies with a humanized anti-CEA X murine anti-(In- DTPA) bispecific antibody construct and Tc-99m/Re-188 labeled peptide," <i>Journal of Nuclear Medicine</i> , Vol. 40, No. 5 Suppl., p 225 (May 1999).
<i>zws</i>	A7	E. Gautherot <i>et al.</i>	"Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens," <i>Journal of Nuclear Medicine</i> , Vol. 39 (11), pp 1937-43 (Nov. 1998).
<i>zws</i>	A8	F.K. Bodere <i>et al.</i>	"Phase I/II total of two-step radioimmunotherapy in medullary thyroid cancer (MTC) using bispecific anti-CEA/anti- DTPA-in antibody and iodine-131-labeled bivalent hapten," <i>Journal of Nuclear Medicine</i> , Vol. 39, No. 5 Suppl., p 246 (May 1998).
<i>zws</i>	A9	M. Bardies <i>et al.</i>	"Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer," <i>Journal of Nuclear Medicine</i> , Vol. 37, pp 1853-1859 (Nov. 1996).
<i>zws</i>	A10	Kraeber-Bodere F. <i>et al.</i>	"Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft," <i>Journal of Nuclear Medicine</i> , Vol. 40 (1), pp 198-204 (Jan. 1999).
<i>zws</i>	A11	M. Hosono <i>et al.</i>	"Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten," <i>Journal of Nuclear Medicine</i> , Vol. 39 (9), pp 1608-13 (Sep. 1998).
<i>duplicate ref.</i>	A12	M.H. Kraenborg <i>et al.</i>	"Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two phase targeting of renal cell carcinoma," <i>Cancer Research</i> , Vol. 55 (23 Suppl.), pp 5864S-5867S (Dec. 1, 1995).


LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

APPLICANT
Hans J. HANSEN *et al.*

FILING DATE
June 22, 1999

GROUP
1643

Date Submitted to PTO: May 18, 2000



Date Submitted to PTO: May 18, 2000			
Sus	A13	M.H. Kranenborg <i>et al.</i>	"Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies," <i>International Journal of Cancer</i> , Vol. 75 (1), pp 74-80 (Jan. 5, 1998).
Sus	A14	E. Gautherot <i>et al.</i>	"Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten," <i>Cancer</i> , Vol. 80, No. Suppl. 12, pp 2618-2623 (Dec. 15, 1997).
Sus	A15	K. Bosslet <i>et al.</i>	"Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy," <i>British Journal of Cancer</i> , Vol. 63/5, pp 681-686 (1991).
Sus	A16	C. Manetti <i>et al.</i>	"Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody -targeted hapten by B-lymphoma cells," <i>Int. J. Cancer</i> , Vol. 63(2), pp 250-6 (1995).
Sus	A17	J. Barbet <i>et al.</i>	"Radioimmunotherapy of LS174T colon carcinoma in nude mice using an iodine-131-labeled bivalent hapten combined with an anti-CEAX anti-indium- DTPA bispecific antibody," <i>Tumor Biology</i> , Vol. 18, No. Suppl. 2, p 31 (Sept. 1997).
EXAMINER		DATE CONSIDERED	
David A. Saunders		2/7/01	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.